Prevalence of retinopathy based on the final human grade in the worst eye for each centre and for all three centres combined
| Final human retinopathy grade | Number of episodes in each DESP (column %) | |||
|---|---|---|---|---|
| NEL | GS | SEL | Combined (column %) | |
| R0M0 | 7031 (69.4%) | 6867 (68.1%) | 7414 (72.9%) | 21 312 (70.1%) |
| R1M0 | 2252 (22.2%) | 2645 (26.2%) | 1994 (19.6%) | 6891 (22.7%) |
| R1M1 | 368 (3.6%) | 287 (2.8%) | 346 (3.4%) | 1001 (3.3%) |
| R2 | 127 (1.3%) | 50 (0.5%) | 113 (1.1%) | 290 (1%) |
| R2M0 | 38 (0.4%) | 24 (0.2%) | 31 (0.3%) | 93 (0.3%) |
| R2M1 | 89 (0.9%) | 26 (0.3%) | 82 (0.8%) | 197 (0.6%) |
| R3 | 57 (0.6%) | 49 (0.5%) | 66 (0.6%) | 172 (0.6%) |
| R3M0 | 28 (0.3%) | 23 (0.2%) | 20 (0.2%) | 71 (0.2%) |
| R3M1 | 29 (0.3%) | 26 (0.3%) | 46 (0.5%) | 101 (0.3%) |
| Ungradable | 302 (3%) | 193 (1.9%) | 244 (2.4%) | 739 (2.4%) |
| Total | 10 137 | 10 091 | 10 177 | 30 405 |
Retinopathy grades: No retinopathy (R0); mild-to-moderate non-proliferative retinopathy (R1); non-referable maculopathy (M0); ungradable images (U); referable maculopathy (M1), moderate-to-severe non-proliferative retinopathy (R2) and proliferative retinopathy (R3).8 9
DESP, Diabetic Eye Screening Programme; GS, Gloucestershire; NEL, North East London; SEL, South East London.